(NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN toremifene) (NN therapy))) (PP (IN on) (NP (NP (NN serum) (NN immunoglobulin) (NNS levels)) (PP (IN in) (NP (NN breast) (NN cancer))))) (. .))
(S (NP-SBJ-COOD (NP (NNS Estrogens)) (CC and) (NP (NNS anti-estrogens))) (VP (VBP enhance) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (ADJP (NN immunoglobulin) (-LRB- -LRB-) (NN Ig) (-RRB- -RRB-) (NN -secreting)) (NNS cells)))) (PP (IN in) (NP (ADJP (NN pokeweed) (NN mitogen) (-LRB- -LRB-) (NN PWM) (-RRB- -RRB-) (JJ -stimulated)) (NN lymphocyte) (NNS cultures)))) (. .))
(S (NP-SBJ (NP (NNS Lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (SBAR (WHNP-14 (WP who)) (S (NP-SBJ (-NONE- *T*-14)) (VP (VBP have) (VP (VBN received) (NP (NN anti-estrogen) (NN therapy))))))))) (VP (VBP show) (NP (NP (NP (JJ similar) (NN enhancement)) (PP (IN of) (NP (JJ Ig-secreting) (NNS cells))))) (PP-TMP (IN after) (NP (NN PWM) (NN stimulation)))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ-15 (NP (DT the) (NN effect)) (PP (IN of) (NP (NN anti-estrogen) (-LRB- -LRB-) (NN toremifene) (-RRB- -RRB-) (NN therapy))) (PP (IN on) (NP (NP (NP (NP (NN serum) (NN immunoglobulin)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN IgA)) (, ,) (NP (NN IgM)) (, ,) (NP (NN IgG))) (-RRB- -RRB-))) (NNS levels)) (PP (IN in) (NP (NN breast) (NN cancer) (NNS patients)))))) (VP (VBD was) (VP (VBN investigated) (NP (-NONE- *-15)))) (. .))
(S (NP-SBJ-16 (NN Serum) (NN Ig) (NNS levels)) (VP (VBD were) (VP (VBN followed) (NP (-NONE- *-16)) (NP-TMP (QP (RB up) (TO to) (CD two)) (NNS years)) (PP-TMP (PP-COOD (PP (IN after) (NP (-NONE- *RNR*-17))) (CC or) (PP (IN during) (NP (-NONE- *RNR*-17)))) (NP-17 (DT the) (NN therapy))))) (. .))
(S (NP-SBJ (DT An) (JJ unexpected) (NN finding)) (VP (VBD was) (SBAR-PRD (IN that) (S (NP-SBJ (DT the) (NN Ig) (NNS levels)) (VP (VBD decreased) (PP-TMP (IN during) (NP (DT the) (JJ follow-up) (NN period))))))) (. .))
(S (NP-SBJ-18 (DT This) (NN decrease)) (VP (VBD was) (VP (VBN seen) (NP (-NONE- *-18)) (PP-COOD (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP-19 (WP who)) (S (NP-SBJ (-NONE- *T*-19)) (VP (VBD responded) (PP (TO to) (NP (DT the) (NN therapy)))))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP-20 (WP who)) (S (NP-SBJ (-NONE- *T*-20)) (VP (VBD did) (RB not) (VP (-NONE- *?*)))))))))) (. .))
